Spironolactone
What studies of spironolactone found
At a glance, by condition
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 4 findings, all C.
4 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Spironolactone might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Spironolactone · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Symptoms
Post-exertional malaise1 study · 1 (few people) person took spironolactone Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · over one month · 25 mg daily; 100 mg daily (few people)
Post-exertional malaise improved.
The evidence is very uncertain about the effect of spironolactone on post-exertional malaise in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Spironolactone for ME/CFS in a Patient Homozygous for rs5522 (I180V): A Case Report (2026)
- People in the study
- 1 in the study
- Dose
- 25 mg daily; 100 mg daily
- Outcome
- post-exertional malaise
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Sleep1 study · 1 (few people) person took spironolactone Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · over one month · 25 mg daily; 100 mg daily (few people)
Sleep improved.
The evidence is very uncertain about the effect of spironolactone on sleep in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Spironolactone for ME/CFS in a Patient Homozygous for rs5522 (I180V): A Case Report (2026)
- People in the study
- 1 in the study
- Dose
- 25 mg daily; 100 mg daily
- Outcome
- restorative sleep
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 1 (few people) person took spironolactone Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · over one month · 25 mg daily; 100 mg daily (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of spironolactone on daily functioning in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)
White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): SF-36 – Role limitations due to emotional problems, better.
Shown, not counted: spironolactone was given together with other treatments.
See the 1 study
-
Spironolactone for ME/CFS in a Patient Homozygous for rs5522 (I180V): A Case Report (2026)
- People in the study
- 1 in the study
- Dose
- 25 mg daily; 100 mg daily
- Outcome
- functional restoration
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person took spironolactone Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · over one month · 25 mg daily; 100 mg daily (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of spironolactone on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Spironolactone for ME/CFS in a Patient Homozygous for rs5522 (I180V): A Case Report (2026)
- People in the study
- 1 in the study
- Dose
- 25 mg daily; 100 mg daily
- Outcome
- improvement sustained
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Studies of combinations
Outcomes that only studies of spironolactone given together with other treatments looked at. Shown, not graded: they can’t tell what spironolactone did alone.
Low mood or anxiety ME/CFS
Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)
White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): SF-36 – Mental health, better.
Shown, not counted: spironolactone was given together with other treatments.
Autonomic symptoms ME/CFS
Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)
White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): Dizziness level, no clear difference.
Shown, not counted: spironolactone was given together with other treatments.
Breathlessness ME/CFS
Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)
White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): Dyspnoea/shortness of breath level, no clear difference.
Shown, not counted: spironolactone was given together with other treatments.
Fatigue ME/CFS
Combination: Spironolactone + Colchicine + Low-dose naltrexone + Multivitamins (Centrum)
White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024): Fatigue level, no clear difference.
Shown, not counted: spironolactone was given together with other treatments.
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
25 mg at the start
- 2Top dose
Most often 25 mg (2 of 2 studies)
Doses across 2 studies
25 to 25 mg.
Each study’s dose, as printed
- 25 mg daily; 100 mg daily Spironolactone for ME/CFS in a Patient Homozygous for rs5522 (I180V): A Case Report (2026)
- 25 mg/day White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome (2024)
All papers
- Pharmacological prevention of post-COVID syndrome in real-world clinical practice: results of a 36-month prospective cohort study2026 · compared with another group · 221 in the study · 159 with outcome data
Summary
This prospective observational cohort study examined drugs used in acute COVID-19 and early post-acute care for later post-COVID syndrome. It enrolled 221 adults hospitalized with COVID-19 pneumonia at Kharkiv City Clinical Hospital No 13. Groups were compared without randomisation. Drugs were dexamethasone 6 мг/добу throughout hospitalization; methylprednisolone 500 мг/добу for 3 днів; remdesivir 200 мг then 100 мг/добу for 5 — 10 діб; antibiotics; edaravone 60 мг/добу for 10 днів; and quercetin 80 мг and L-arginine 1000 мг three times daily, or spironolactone 50 мг/добу for the first month after discharge. Outcomes were exercise-tolerance recovery at 1 month and absence of PCS symptoms at 3, 12 and 36 months. 159 patients completed 36 months; 62 were lost to follow-up. No statistically significant risk reduction was reported at any stage for methylprednisolone, antibiotics, remdesivir, quercetin, or L-arginine. Dexamethasone: significant reduction at 3 months (RR 0,67; NNT = 2,86), RR 0,62 and 1,10 at 12 and 36 months without significance. Edaravone: reduction at 1 month (RR 0,27; NNT = 4,36) that lost significance later. Spironolactone: no significant effect at 1 and 3 months (RR 0,63 and 0,99); significant reductions at 12 months (RR 0,38; NNT = 3,51) and 36 months (RR 0,53; NNT = 4,78); adjusted 12-month RR 0,30 (95 % CI 0,14 — 0,66). L-arginine at 1 month: RR 0,29 (p = 0,051). At 36 months, antibiotics and methylprednisolone had non-significant increased RR to 1,93 and 1,53. No harms data and no withdrawals for harms were reported in the recorded data.
- Spironolactone for ME/CFS in a Patient Homozygous for rs5522 (I180V): A Case Report2026 · case report · 1 in the study
Summary
This single case report describes a 48-year-old woman with a 28-year history of ME/CFS, diagnosed in 1998 at a specialized chronic fatigue syndrome clinic based on clinical criteria. One patient was enrolled, started spironolactone at 25 mg daily and titrated to 100 mg daily; improvement was reported over one month. There was no comparison group. Concurrent treatments at spironolactone initiation included thyroid replacement including T3, oral iron supplementation, low-dose naltrexone (0.5 mg), antidepressants, and progesterone. The report states that within 48 hours of reaching therapeutic dose she reported the first restorative sleep in 28 years; post-exertional malaise resolved within 3 days; significant functional restoration was achieved within 2 weeks; and improvement was sustained for over one month on 100 mg daily. Blood pressure was reported as stable, 124/82 mmHg pre-treatment and 134/80 mmHg at two weeks. Mild fluid retention was managed with addition of low-dose hydrochlorothiazide at two weeks; withdrawals for harms were not reported. The authors state this is a single case report and cannot establish causation; they note the patient’s improvement may be influenced by factors beyond spironolactone, including concurrent treatments or natural disease fluctuations, and that placebo effect cannot be entirely excluded.
- Identification of CD8 T-cell dysfunction associated with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID and treatment with a nebulized antioxidant/anti-pathogen agent in a retrospective case series.2024 · case report · 8 in the study
Summary
This retrospective case series enrolled 8 patients, 4 with ME/CFS and 4 with Long COVID, recruited from the UMass Chan community, UMass Memorial Health Center, and The Salerno Center for Complementary Medicine, New York. Patients self-selected to receive a nebulized antioxidant/anti-pathogen agent, Inspiritol, at a recommended dose of 5.0 mL TID by nebulizer; treatment lasted 3–15 months (ME/CFS 204–519 days; Long COVID 72–519 days). There was no comparison group; outcomes were within-patient changes in self-reported symptom severity (0–10, higher worse) and CD8 T-cell cytokine production. In all 8 patients, overall self-reported symptom severity fell by a mean of 4.4 points (54% decrease); PEM fell by 3.9 points (54% decrease), dysnomia by 3.8 points (64% decrease), and difficulty concentrating by 3.9 points (73.8% decrease). All 8 patients had a positive response. In 7 patients with ICS data, IFNγ-producing CD8 T cells increased 3.6-fold (p = 0.006) and TNFα-producing cells 2.5-fold (p = 0.016); one Long COVID patient’s ICS data were unavailable because the sample degraded during shipping. Mild cough in some patients was controlled by slowing administration; no serious treatment-associated side effects or laboratory anomalies were noted. The authors state numbers were small.
- White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome2024 · combination: given with other treatments
Summary
Why: the authors investigated neuroimaging and clinical changes linked with a synergistic off-label treatment (SOT) for ME/CFS. Who: 8 treated ME/CFS patients (SOT) and 8 age-gender matched treatment-naïve ME/CFS patients (control); SOT patients were treated by Dr. do Campo in routine practice, controls randomly selected from an ongoing neuroimaging study. Treatment: oral spironolactone 25 mg/day, colchicine 0.5 mg/day, low dose naltrexone 1.5–4.5 mg/day, and multivitamins for more than 6 months; mean time on protocol 27.75 (10.82) months. Measured: HADS, SF-36, CCC-JDC, standing-task items, and diffusion-weighted imaging. Findings: SOT showed lower HADS depression (8.83 (3.37) vs 13.5 (3.67), p = 0.04*) and higher SF-36 Mental Health (69.33 (13.78) vs 43.2 (15.85), p = 0.01*), plus higher SF-36 Role limitations due to emotional problems (77.78 (27.22) vs 27.78 (44.31), p = 0.04*) and Mental component summary (46.49 (5.38) vs 38.02 (8.89), p = 0.02*). CCC-JDC fell from baseline 20.25 ± 2.92 to post-treatment 10.86 ± 4.49 (PBonf < .001). DWI showed higher FA and lower diffusivity in SOT (PFWE ≤ .05). No significant differences were reported for HADS anxiety (p = 0.23), SF-36 Physical component summary (p = 0.73), or Fatigue level (p = 0.2). Two selected participants were excluded; one was 68 years old and another had to stop spironolactone after developing POTS.